CD4-bearing human thymic dendritic cells as potential targets for HIV infection.

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

CD4-bearing human thymic dendritic cells as potential targets for HIV infection.

Annu Conf Australas Soc HIV Med. 1993 Oct 28-30;5:106 (poster no. 63). Unique Identifier : AIDSLINE ASHM5/94348922
Sotzik F; Shortman K; Walter and Eliza Hall Institute of Medical Research, Royal; Melbourne Hospital, Parkville, Victoria.

Abstract: The intention of the project was the isolation of CD4-bearing T-precursor thymocytes. This laboratory has found these to be the earliest T-precursors in the murine thymus with T cell receptor genes in the germline, unrearranged state. In order to identify the human equivalent, CD34 and CD7 expression has been examined on cells lacking certain markers of mature T cells. CD7+34+thymocytes bearing differing levels of CD2 were only observed amongst CD4-cells. No CD4+ cell resembling the earliest murine T-precursor was found. However a CD4(high) human thymic dendritic cell was discovered, which was class II MHC(high) class I MHC(high) CD44+ CD1-2-3-7-8-16-34-, negative for monocyte, NK and B cell surface markers. More peripheral blood cells (PBL) (i.e. 10(2)x) than dendritic cells were required to stimulate T cells equally well in a mixed lymphocyte reaction (MLR) culture system. Cells sorted into simple culture medium in Terasaki wells and incubated at 37 degrees C assumed dendritic morphology after 2 to 3 hours. In collaboration with the NCHVR and Macfarlane Burnet Centre, the capacity of these cells to be infected with HIV will be assessed.

Keywords: Antigens, CD4/*ANALYSIS Cells, Cultured CD4-Positive T-Lymphocytes/IMMUNOLOGY/*MICROBIOLOGY Dendritic Cells/IMMUNOLOGY/*MICROBIOLOGY Human HIV/*IMMUNOLOGY/PATHOGENICITY Thymus Gland/*CYTOLOGY Virulence ABSTRACT
941230
M94C4305

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .